<DOC>
	<DOCNO>NCT01271166</DOCNO>
	<brief_summary>This Phase I , dose find , multicentre study evaluate maximal tolerate dose Glivec速 combination mFOLFOX-Avastin速 . Patients enrol dose level 3 patient cohort . Additional cohort enrol , dose level open , subject toxicity observe . Once MTD determine dose level re-opened extra patient , total 15 , enrol .</brief_summary>
	<brief_title>Glivec速 Plus m-FOLFOX Avastin速 Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Histologically confirm , locally advanced , recurrent metastatic colorectal cancer ECOG 0 1 Measurable disease Prior first line therapy advance disease Significant bulk metastatic disease rapid progression If prior adjuvant therapy , relapse within 6 month 5FU base regimen 12 month oxaliplatin base regimen Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Colorectal ,</keyword>
	<keyword>Cancer</keyword>
</DOC>